Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Pancreatic Neoplasms 8Colorectal Neoplasms 6Rectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Wilms Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic to Liver 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Metastatic Gastric Adenocarcinoma 1Malignant Ascites 1Locally Advanced Rectal Cancer 1Hepatoblastoma 1Gastroesophageal Junction Adenocarcinoma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1

Interventions

Cisplatin 27Gemcitabine 22toripalimab 19Radiotherapy, Intensity-Modulated 18Capecitabine 10Radiotherapy 8Magnetic Resonance Spectroscopy 8nimotuzumab 7camrelizumab 7Specimen Handling 7Immune Checkpoint Inhibitors 7spartalizumab 5Drug Therapy 5Docetaxel 5Nivolumab 4Biopsy 4sintilimab 3Surgical Procedures, Operative 3Radiosurgery 3Platinum 3Fluorouracil 3Endoscopy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tislelizumab 2pembrolizumab 2irinotecan sucrosofate 2envafolimab 2apatinib 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Carcinoma × irinotecan sucrosofate × Clear all
NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06657690 2025-01-10

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Sun Yat-sen University

Phase 2 Recruiting
56 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡